Dimension Inx, a biofabrication company developing regenerative medical products, announced two new appointments to its Board of Directors. Veteran medical device executives Dianne Hayes Blanco and James Koziarz, Ph.D., join company founders Caralynn Nowinski Collens, M.D., Adam Jakus, Ph.D., and Ramille Shah, Ph.D., becoming the company’s first outside directors.
“Dianne and Jim bring invaluable perspective, having both served as startup CEOs and Fortune 200 corporate executives,” said Dr. Collens. “Their collective expertise in leading and advising medical technology companies through rapid growth will be an invaluable asset moving forward.”
“Having watched the organization mature over the past year, I am encouraged by the team’s progress on product development and I am excited to work with the team to further advance our pipeline of assets both internally and through strategic partnerships,” said Dr. Koziarz.
“Dimension Inx is solving critical patient needs while also satisfying key surgeon requirements – an important balance,” said Ms. Blanco. “I look forward to joining the founders and our partners on this journey to achieve a future where tissue regeneration is a normal course of treatment.”
Dimension Inx utilizes its patented 3D-Painting System to design and manufacture next-generation biomaterials and 3D-printed products for organ and tissue repair and regeneration. The system confers necessary compositional and microstructural features to surgical implants to promote healing and tissue regeneration. The company’s first therapeutic products are in development for applications in bone reconstruction as well as dental applications.
Dianne Hayes Blanco
Ms. Blanco is a seasoned executive with 25 years of experience building and leading medical device companies. She was the founder and former CEO of Orteq Ltd., which develops advanced biodegradable medical devices for orthopedic and sports injuries. Previously, she served as president of three successive Baxter International divisions and head of PneumRx, which was acquired by BTG PLC. Ms. Blanco has been a board director for several medical technology companies in the U.S. and Europe.
James Koziarz, Ph.D.
Dr. Koziarz is the former president and CEO of Rubicon Genomics, a leader in genomic diagnostics, which was acquired by Takara Bio in 2017. He spent 25 years in the Diagnostics Division of Abbott Laboratories, including 11 years as a corporate officer where he managed product development, manufacturing, and new technology management. Since retirement from Abbott, Dr. Koziarz has served as a board director and advisor to several early stage, venture-backed life sciences companies.